A pharmacist-led, new digital intervention that improves patient safety when prescribing medication in general practice reduced rates of hazardous prescribing by more than 40* per cent, 12 months after it had been introduced to 43 GP practices in Salford, finds a new study**. Due to its success, plans are underway to roll it out across Greater Manchester.
Prescribing and medication are one of the biggest causes of patient safety incidents and the third WHO Global Patient Safety Challenge is focussed on Medication without Harm***. The SMASH**** intervention addresses this. It was developed by researchers at the National Institute for Health Research Greater Manchester Patient Safety Translational Research Centre (NIHR GM PSTRC), which is a partnership between The University of Manchester and Salford Royal hospital in collaboration with The University of Nottingham.
Pharmacists working in general practice use the SMASH dashboard to identify patients who are exposed to potentially hazardous prescribing. For example, patients with a history of internal bleeding may be prescribed medications such as aspirin which could increase the risk of further internal bleeds without prescribing other treatments to protect them. SMASH identifies this and warns healthcare professionals about it, who can then decide on a possible course of action.
The intervention is unique due to its ability to provide near real time feedback to prescribers as it updates every evening.
Professor Darren Ashcroft, Research Lead for the Medication Safety theme at the GM PSTRC, said: "We worked with the Safety Informatics theme at the GM PSTRC to develop then test SMASH. It is designed to improve patient safety in general practice by reducing potential problems made when prescribing medication and inadequate blood-test monitoring. It brings together people and data to reduce these common medication safety problems that all too often can cause serious harm.
"It works when a GP practice has a clinical pharmacy team. These teams working in general practices across Salford used the insights identified by SMASH to become "Champions for Change". In doing so, they achieved marked improvements in rates of hazardous prescribing over the 12 month study period. Importantly, at the end of the 12 month study the success of the intervention was sustained which is encouraging. Our efforts are now focussed on scaling up the SMASH intervention to benefit the whole Greater Manchester population."
The researchers monitored SMASH in each of the GP practices where it was trialled for a year and evaluated its success.
Professor Niels Peek, Research Lead for the Safety Informatics theme at the GM PSTRC, said: "SMASH capitalises on the unique digital infrastructure that already existed in Salford and will soon be available for 2.8 million people in Greater Manchester. This will create an integrated health system that continuously learns and improves the quality of its services."
The intervention builds on the principles of PINCER, an intervention developed by The University of Nottingham and The University of Manchester, and supported by the GM PSTRC. SMASH uses a set of 13 prescribing safety indicators developed by experts for PINCER. An example is the prescription of an oral non-steroidal anti-inflammatory drug (NSAID), without also prescribing an ulcer healing drug, to a patient aged over 65.
PINCER is proven to reduce hazardous prescribing and has been rolled out by Academic Health Science Networks (AHSNs) to 40% of GP practices in England as part of co-ordinated approach to reduce medication errors in primary care by the national AHSN Network. Due to the success of SMASH in Salford, Health Innovation Manchester, the organisation responsible for accelerating proven innovation into Greater Manchester's health and social care services and part of the AHSN Network, is currently working to roll it out across Greater Manchester.
Amanda Risino, Chief Operating Officer at Health Innovation Manchester, said: "SMASH is a great innovation and there is a huge opportunity to be realised by sharing this innovation across the Greater Manchester city region. Not only will it help patients at direct risk of medication-related harm, but by also using data from multiple health and social care organisations we can drive improvements in prescribing safety and effectiveness across all care settings."
Notes for editors:
***Safety Medication Dashboard
Greater Manchester Patient Safety and Translational Research Centre
Mary Vingoe - Communications Manager
Phone: 07738 8880152
About the NIHR Greater Manchester Patient Safety Translational Research Centre: The NIHR Greater Manchester Patient Safety Translational Research Centre is a partnership between The University of Manchester and Salford Royal NHS Foundation Trust in collaboration with The University of Nottingham, which aims to make healthcare safer in primary care and transitions of care. It's funded by the National Institute for Health Research (NIHR) for five years from 2017 until 2022 and is one of three PSTRC in England. The Greater Manchester PSTRC conducts resea//rch across four themes: Safety Informatics, Medication Safety, Safer Care Systems and Transitions, and Safety in Marginalised Groups.
For more information visit - http://www.patientsafety.manchester.ac.uk/
About the University of Manchester: The University of Manchester, a member of the prestigious Russell Group, is the UK's largest single-site university with 38,600 students. It has 20 academic schools and hundreds of specialist research groups undertaking pioneering, multi-disciplinary teaching and research of worldwide significance. The University is one of the country's major research institutions, rated fifth in the UK in terms of 'research power' (REF 2014), and has had no fewer than 25 Nobel laureates either work or study there. The University had an annual income of £1 billion in 2014/15. Visit http://www.manchester.ac.uk
About The National Institute for Health Research (NIHR): The NIHR is the nation's largest funder of health and care research. The NIHR:
- Funds, supports and delivers high quality research that benefits the NHS, public health and social care
- Engages and involves patients, carers and the public in order to improve the reach, quality and impact of research
- Attracts, trains and supports the best researchers to tackle the complex health and care challenges of the future
- Invests in world-class infrastructure and a skilled delivery workforce to translate discoveries into improved treatments and services
- Partners with other public funders, charities and industry to maximise the value of research to patients and the economy
The NIHR was established in 2006 to improve the health and wealth of the nation through research, and is funded by the Department of Health and Social Care. In addition to its national role, the NIHR supports applied health research for the direct and primary benefit of people in low- and middle-income countries, using UK aid from the UK government.
This work uses data provided by patients and collected by the NHS as part of their care and support and would not have been possible without access to this data. The NIHR recognises and values the role of patient data, securely accessed and stored, both in underpinning and leading to improvements in research and care. http://www.nihr.ac.uk/patientdata
About Health Innovation Manchester
Health Innovation Manchester brings together health, academia and industry as part of an academic health science system with the aim of accelerating innovation to improve people's health and wellbeing. Our aim is to make Greater Manchester the most innovative health and social care system in the UK, a place internationally renowned for its ability to apply the skills of industry innovators, academic and clinical colleagues, to meet the needs of patients and citizens. For more information visit healthinnovationmanchester.com